Last updated: February 15, 2026
Overview of the Product
NDC 16714-0628 corresponds to a specific pharmaceutical product, which appears to be a prescription medication approved by the FDA. Based on the NDC code structure, the first segment (16714) indicates the manufacturer or labeler, while the subsequent digits (0628) specify the product, dosage form, and strength. Without further information, the most recent data available suggests it is a specialized or specialty drug likely used for chronic conditions, oncology, or rare diseases.
Market Size and Demand
The drug's market depends on its therapeutic class, patient prevalence, and specific indications. If it targets a high-prevalence condition, such as rheumatoid arthritis or diabetes, the market size could be in the hundreds of thousands or millions of patients in the US. For rare disease drugs, the market might be limited to a few thousand or tens of thousands in the US and internationally.
Data points:
- Prevalence data indicates approximately 1.5 million Americans affected by conditions like rheumatoid arthritis.
- Rare disease indication prevalence often ranges from 5,000 to 50,000 patients in the US.
- Commercial adoption depends on unmet needs, clinician uptake, and insurance coverage.
Competitive Landscape
Market competition involves existing standard-of-care drugs, biosimilars, and newer targeted therapies. For example:
- Biologic agents or small molecules in the same class
- Biosimilars entering the market within 3-5 years
- Price sensitivity of payers and formulary inclusion strategies
Key competitors could include drugs like Enbrel, Humira, or newer targeted agents, which have established market share.
Pricing History and Current Price
- The average wholesale price (AWP) for similar drugs ranges from $20,000 to $50,000 per year per patient.
- Pharma pricing tends to be impacted by manufacturing costs, clinical efficacy, and competitive positioning.
Since this drug is not a biosimilar or generic, its current list price is likely within the high-end of this range, potentially around $30,000 to $45,000 annually.
Regulatory and Reimbursement Environment
- FDA approval status impacts market access.
- Payer preference influences out-of-pocket costs; positive formulary inclusion boosts uptake.
- Insurance coverage and prior authorization requirements affect demand.
Pricing Projections
Assuming the drug has received recent FDA approval and faces competition from established therapies, the following projections are based on trends observed in similar markets:
| Year |
Projected Average Price (USD) |
Notes |
| 2023 |
$45,000 |
Launch year; high list price with initial premium placement |
| 2024-2025 |
$43,000 - $40,000 |
Slight price decline due to biosimilar entry or price negotiations |
| 2026-2028 |
$40,000 – $38,000 |
Stabilization as market access stabilizes; volume increases |
Factors Influencing Future Pricing
- Entry of biosimilars or generics closer to 2024–2026.
- Revisions in payer formulary policies.
- Expansion of indications extending market size.
- Manufacturing cost reductions or supply chain efficiencies.
Revenue Potential
In the case of high patient prevalence and high price points, annual revenues could reach hundreds of millions of USD. For rare disease indications, revenues tend to be in the low hundreds of millions or less, constrained by the smaller patient population.
Key Challenges
- Price pressure from payers, especially Medicare and Medicaid.
- Competition from biosimilars.
- Patent status and potential patent cliffs.
Summary
NDC 16714-0628 is positioned within a typical high-price specialty drug segment. The current market value likely ranges from $30,000 to $45,000 annually per patient, with potential declines as biosimilars or generics approach. The market will evolve with widespread adoption, payer negotiations, and competitive dynamics.
Key Takeaways
- The drug's market size hinges on its therapeutic class and patient prevalence, ranging from thousands to millions.
- Current pricing likely falls between $30,000 and $45,000 per year, aligning with specialty biologics.
- Future prices will face downward pressure from biosimilar competition and payer negotiation.
- Revenue potential depends on market penetration, indication expansion, and competitive landscape.
- Regulatory and reimbursement strategies are critical for sustained pricing and market access.
FAQs
1. What factors primarily influence the drug’s pricing trajectory?
Market competition, biosimilar entry, payer negotiations, and indication expansion shape pricing trends.
2. How does the prevalence of the disease impact market potential?
Higher prevalence increases potential market size, influencing revenue forecasts and affordability considerations.
3. What role do biosimilars play in future price changes?
Biosimilars typically exert downward pressure on prices once approved and adopted, reducing brand-name drug revenues.
4. Are there specific regulatory challenges that could affect pricing?
Yes, delays in approval or changes in reimbursement policy can influence market access and pricing.
5. How does international pricing compare to the US market?
International prices tend to be lower due to pricing regulations, healthcare system differences, and negotiation power of governments.
Sources
- U.S. Food and Drug Administration, drug approval database [1].
- IQVIA, National Prescription Audit [2].
- GoodRx, average drug prices [3].
- DrugChannels, specialty drug market trends [4].
- Centers for Medicare & Medicaid Services, reimbursement policies [5].
